drugset / Trial / NCT05926700
Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment
NaSingle-groupOpen-labelTreatment
Summary
Objective to evaluate the efficacy and safety of candonilimab combined with anlotinib in the treatment of progressive or metastatic soft tissue sarcoma that failed previous first-line standard therapy.
Timeline
- Start
- 2024-02-28
- Primary completion
- 2026-12-01
- Completion
- 2027-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |